ArticleMolecular psychiatry2007
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
Article in Molecular psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 147 citations in OpenAlex.
- Gα13 Overexpression in the Medial Prefrontal Cortex Disrupts Social Behavior Through the Adcyap1/cAMP/PKA/NMDAR Pathway.Schizophrenia bulletin · 2026Article
- Bed Nucleus of the Stria Terminalis PACAP Signaling in the Dorsal Medial Habenula Mediates Depression-Related Behavioral Responses After Chronic Stress.Biological psychiatry · 2026Article
- More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?Journal of molecular neuroscience : MN · 2025Review
- The role of amphipathic and cationic helical peptides in Parkinson's disease.Protein science : a publication of the Protein Society · 2025Review
- Pituitary adenylate cyclase-activating polypeptide plays a role in neuropsychiatric and substance use disorders: sex-specific perspective.Frontiers in neuroscience · 2025Review
- The role of depression in the progression of tumor cell inflammation and the potential regulatory mechanisms of aerobic exercise: a narrative review from molecular and cellular perspectives.Frontiers in psychiatry · 2025Review
- Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia.The American journal of psychiatry · 2024Article
- Alterations in pituitary adenylate cyclase-activating polypeptide in major depressive disorder, bipolar disorder, and comorbid depression in Alzheimer's disease in the human hypothalamus and prefrontal cortex.Psychological medicine · 2023Article
- The functional heterogeneity of PACAP: Stress, learning, and pathology.Neurobiology of learning and memory · 2023Review
- Increased pituitary adenylate cyclase-activating peptide genes expression in the prefrontal cortex in schizophrenia in relation to suicide.Frontiers in molecular neuroscience · 2023Article
- Editorial: Neuropeptide GPCRs in neuroendocrinology, Volume II.Frontiers in endocrinology · 2023Article
- Identification ofFrontiers in molecular neuroscience · 2023Article
- Immunomodulatory Role of Neuropeptides in the Cornea.Biomedicines · 2022Review
- Frequent lineage-specific substitution rate changes support an episodic model for protein evolution.G3 (Bethesda, Md.) · 2021Article
- PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- PACAP is a pathogen-inducible resident antimicrobial neuropeptide affording rapid and contextual molecular host defense of the brain.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Probing theFrontiers in neuroscience · 2021Review
- PACAP-PAC1 Signaling Regulates Serotonin 2A Receptor Internalization.Frontiers in endocrinology · 2021Article
- Neural innervation as a potential trigger of morphological color change and sexual dimorphism in cichlid fish.Scientific reports · 2020Article
- Parallel signaling pathways of pituitary adenylate cyclase activating polypeptide (PACAP) regulate several intrinsic ion channels.Annals of the New York Academy of Sciences · 2019Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.